

**The Pharmacogenetic Footprint of ACE Inhibition: a Population-Based  
Metabolomics Study**

Authors:

Elisabeth Altmaier, Cristina Menni, Margit Heier, Christa Meisinger, Barbara Thorand, Jan Quell,  
Michael Kobl, Werner Römisch-Margl, Ana M Valdes, Massimo Mangino, Melanie Waldenberger,  
Konstantin Strauch, Thomas Illig, Jerzy Adamski, Tim Spector, Christian Gieger, Karsten Suhre,  
Gabi Kastenmüller

Journal: PLOS One

Corresponding author:

Gabi Kastenmüller

Helmholtz Zentrum München, German Research Center for Environmental Health,

Ingolstädter Landstr. 1,

D-85764 Neuherberg, Germany

e-mail: [g.kastenmueller@helmholtz-muenchen.de](mailto:g.kastenmueller@helmholtz-muenchen.de)

**S1 Table:** Characteristics of the population related to the intake of ACE inhibitors

	<b>Intake of ACE inhibitors</b>	
	<b>Mean (SD) or n (%)</b>	
	<b>Yes (n=282)</b>	<b>No antihypertensives (n=1079)</b>
<b>Age</b>	65.97 (7.7)	58.04 (8.2)
<b>Gender</b>		
Male	165 (12.1)	493 (36.2)
Female	117 (8.6)	586 (43.1)
<b>HDL-cholesterol (mmol/l)</b>	1.34 (0.3)	1.51 (0.3)
<b>LDL-cholesterol (mmol/l)</b>	3.42 (0.8)	3.71 (0.9)
<b>Total cholesterol (mmol/l)</b>	5.47 (0.9)	5.85 (1.0)
<b>Triglycerides (mmol/l)</b>	1.69 (1.0)	1.44 (1.1)
<b>BMI kg/m<sup>2</sup></b>	30.55 (5.0)	26.94 (4.2)
<b>Diabetes mellitus</b>		
Yes	70 (5.1)	39 (2.9)
No	212 (15.6)	1039 (76.3)
<b>Hypertension</b>		
Yes	261 (19.2)	51 (3.7)
No	21 (1.5)	1026 (75.4)
<b>Intake of beta-blockers</b>		
Yes	139 (10.2)	0 (0)
No	143 (10.5)	1079 (79.3)
<b>Intake of diuretics</b>		
Yes	178 (13.1)	0 (0)
No	104 (7.6)	1079 (79.3)